MetaCap

ProKidney (PROK) vs Sana Biotechnology (SANA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sana Biotechnology (SANA) has outperformed ProKidney (PROK) over the past year, losing 51.7% versus a loss of 52.5%. Over five years, PROK leads with a -89.5% price change compared with -91.3% for SANA. Sana Biotechnology is the larger company by market cap ($476.4 million vs $415.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PROK-52.51%SANA-51.67%
+63%+2%-58%
Nov 21, 20251 yearNov 20, 2026
PROK-89.52%SANA-92.54%
+37%-32%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PROK versus SANA key metrics
MetricPROKSANA
Share price$1.04$1.59
Market cap$415.21M$476.42M
1-day change-1.89%-8.62%
YTD return-53.57%-60.93%
1-year return-52.51%-51.67%
5-year return-89.49%-91.34%
EPS (TTM)$-0.61$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$893.00K—
Revenue growth (YoY)+1075.00%—
Net income (latest FY)$-68.99M$-244.17M
Operating margin-18477.83%—
Net margin-7725.20%—
52-week high$2.65$5.49
52-week low$0.87$1.57
Distance from 52-week high-60.75%-71.04%
Analyst consensusbuystrong_buy
Avg. price target upside+525.00%+438.99%
Average volume1.44M3.30M
Shares outstanding209.63M299.63M
Employees231142
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

About Sana Biotechnology

SANA stock →

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

PROK vs SANA FAQ

Which is bigger, ProKidney or Sana Biotechnology?

Sana Biotechnology (SANA) is larger, with a market capitalization of $476.42M compared with $415.21M for ProKidney (PROK).

Which stock has performed better over the past year, PROK or SANA?

SANA returned -51.67% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.

Are ProKidney and Sana Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons